Active Ingredient History
Acalabrutinib, also known as ACP-196, is a novel irreversible second-generation Bruton’s tyrosine kinase (BTK) inhibitor, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway and that, was rationally designed to be more potent and selective than ibrutinib. This drug in clinical trials phase III for treatment the treatment of relapsed chronic lymphocytic leukemia. Also in combination with others drugs, Acalabrutinib in phase II of clinical trials for the treatment Glioblastoma Multiforme, Mantle Cell Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Rheumatoid Arthritis and some others. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Allergy and Immunology (Phase 2)
Anemia, Hemolytic, Autoimmune (Phase 2)
Antigens, CD (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Biological Availability (Phase 1)
Biomarkers (Phase 2)
Burkitt Lymphoma (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Communicable Diseases (Phase 1)
COVID-19 (Phase 3)
Cyclin D1 (Phase 2)
Food Hypersensitivity (Phase 2)
Glioblastoma (Phase 2)
Graft vs Host Disease (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hepatic Insufficiency (Phase 1)
Hodgkin Disease (Phase 1/Phase 2)
Immunoglobulin M (Phase 2)
Leukemia (Phase 1/Phase 2)
Leukemia, B-Cell (Phase 1/Phase 2)
Leukemia, Hairy Cell (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia, Lymphoid (Phase 2)
Leukemia, Prolymphocytic (Phase 1/Phase 2)
Liver Diseases (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Multiple Myeloma (Phase 1/Phase 2)
Neoplasms (Phase 1/Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Peripheral Nervous System Diseases (Phase 2)
Pharmacokinetics (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Therapeutic Equivalency (Phase 1)
Translocation, Genetic (Phase 2)
Transplantation (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue